Published • loading... • Updated
Dupixent demonstrates improved esophageal function in eosinophilic esophagitis (EoE) Phase 4 trial
Summary by CDR – Chain Drug Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Dupixent demonstrates improved esophageal function in eosinophilic esophagitis (EoE) Phase 4 trial
TARRYTOWN, N.Y. – Regeneron Pharmaceuticals and Sanofi today presented results from the REMODEL Phase 4 trial demonstrating that Dupixent (dupilumab) showed significant and clinically meaningful improvements in both esophageal distensibility (a measure of esophageal function) as well as disease-related structural changes to the esophagus compared to placebo in adults with eosinophilic esophagitis (EoE) at week 24. The results reinforce the previ…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
